Ahren — Full Portfolio
2 tracked investments · listed companies and verified rows first
The company develops a 6-base sequencing platform (duet evoC) that simultaneously profiles methylation (5mC, 5hmC), genetic variants, and fragmentomics from a single cfDNA sample.
BiotechDeep TechHealthtechCambridge
Jason Mellad(Executive Officer, Director)Martin Murphy(Director)Bobby Yerramilli-Rao(Director)Somasundaram Subramaniam(Director)Timothy Rink(Director)Thomas Hulme(Director)
Co-investorsThird Point VenturesAhren Innovation CapitalGV (Google Ventures)New Science VenturesSequoia Capital
Constructive Bio is a biotechnology company that rewrites the genetic code to give cells access to non-canonical amino acid building blocks, expanding the range of proteins that can be designed, engineered, and manufactured.
BiotechDeep TechNew Materials
Jason Chin(Professor)
Co-investors+ND CapitalAmadeus Capital PartnersFine Structures VenturesGENERAL INCEPTIONLongeVCOMX Ventures+2 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.